Carbinoxamine

Allergies, Seasonal & perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria & angioedema

Allergies 4-8 mg PO q6-8hr PO; not to exceed 24 mg/day ER: 6-16 mg (7.5-20 mL) PO q12hr

Allergies 2-6 years: 0.2-0.4 mg/kg/day PO divided q6-8hr or 1-2 mg (2.5 mL) PO q6-8hr >6 years: 2-4 mg (5-7.5 mL) PO q6-8hr ER 2-3 years: 3-4 mg (3.75-5 mL) PO q12hr 4-5 years: 3-8 mg (3.75-10 mL) PO q12hr 6-11 years: 6-12 mg (7.5-15 mL) PO q12hr >12 years: 6-16 mg (7.5-20 mL) PO q12hr

Take on an empty stomach with water

Hypersensitivity Concurrency with MAO inhibitors Preemies & neonates Children <2 years Nursing mothers Lower respiratory tract symptoms, eg, asthma

Deaths reported in children 2 years of age and younger treated with carbinoxamine-containing medications; therefore, contraindicated in children aged <2 years May produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of drug; avoid concurrent use of drug with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur Drug has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction Drug contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in susceptible individuals; the overall prevalence of sulfite sensitivity in the general population is unknown and probably low; sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic individuals

Not Classi Pregnancy Published data over decades of use of antihistamines, including carbinoxamine, have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; however, published data specifically evaluating risk of carbinoxamine were not found No animal reproductive studies have been conducted Lactation Based on physical properties of carbinoxamine, it is likely is present in breast milk Drowsiness and irritability in infants exposed antihistamines via breast milk have been reported Postmarketing reports of death in children <2 years exposed to oral carbinoxamine No data are available on effects on milk production Not recommended to breastfeed during treatment

CNS depressants Avoid coadministration Alcohol or other CNS depressants may potentiate the impairment of CNS performance Monoamine oxidase inhibitors Avoid coadministration Monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines Contraindicated (0) Serious (11) calcium/magnesium/potassium/sodium oxybates eluxadoline isocarboxazid metoclopramide intranasal olopatadine intranasal pitolisant selinexor sodium oxybate sofpironium topical tranylcypromine zuranolone

Frequency Not Defined CNS depression Drowsiness Sedation ranging from mild drowsiness to deep sleep (most frequent) Dizziness Lassitude Disturbed coordination Muscular weakness Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common Epigastric distress Anorexia Nausea Vomiting Diarrhea Constipation Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare Tachycardia, palpitation ECG changes (eg, widened QRS) Arrhythmias (eg, extrasystole, heart block) Hypotension Hypertension Dizziness, sedation, and hypotension may occur in geriatric patients Dryness of mouth, nose, and throat Dysuria Urinary retention Impotence Vertigo Visual disturbances Blurred vision Diplopia; tinnitus Acute labyrinthitis Insomnia Tremors Nervousness Irritability Facial dyskinesia Tightness of the chest Thickening of bronchial secretions Wheezing Nasal stuffiness Sweating Chills Early menses Toxic psychosis Headache

Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract